Switch theme
Sign up to access all valuation multiples
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
2005
65
LTM Revenue n/a
LTM EBITDA -$93.1M
-$58.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Larimar Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of -$93.1M.
In the most recent fiscal year, Larimar Therapeutics achieved revenue of n/a and an EBITDA of -$90.6M.
Larimar Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Larimar Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$41.4M | -$90.6M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$35.4M | -$36.9M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Larimar Therapeutics's stock price is $2.
Larimar Therapeutics has current market cap of $120M, and EV of -$58.6M.
See Larimar Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$58.6M | $120M | XXX | XXX | XXX | XXX | $-1.47 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Larimar Therapeutics has market cap of $120M and EV of -$58.6M.
Larimar Therapeutics's trades at n/a LTM EV/Revenue multiple, and 0.6x LTM EBITDA.
Analysts estimate Larimar Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Larimar Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$58.6M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | 0.6x | XXX | XXX | XXX |
| P/E | -1.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 0.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpLarimar Therapeutics's NTM/LTM revenue growth is Infinity%
Larimar Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.4M for the same period.
Over next 12 months, Larimar Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Larimar Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Larimar Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 119% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Larimar Therapeutics acquired XXX companies to date.
Last acquisition by Larimar Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Larimar Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Larimar Therapeutics founded? | Larimar Therapeutics was founded in 2005. |
| Where is Larimar Therapeutics headquartered? | Larimar Therapeutics is headquartered in United States of America. |
| How many employees does Larimar Therapeutics have? | As of today, Larimar Therapeutics has 65 employees. |
| Who is the CEO of Larimar Therapeutics? | Larimar Therapeutics's CEO is Dr. Carole Ben-Maimon, M.D.. |
| Is Larimar Therapeutics publicy listed? | Yes, Larimar Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Larimar Therapeutics? | Larimar Therapeutics trades under LRMR ticker. |
| When did Larimar Therapeutics go public? | Larimar Therapeutics went public in 2020. |
| Who are competitors of Larimar Therapeutics? | Similar companies to Larimar Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Larimar Therapeutics? | Larimar Therapeutics's current market cap is $120M |
| What is the current EBITDA of Larimar Therapeutics? | Larimar Therapeutics's last 12-month EBITDA is -$93.1M. |
| What is the current EV/EBITDA multiple of Larimar Therapeutics? | Current EBITDA multiple of Larimar Therapeutics is 0.6x. |
| Is Larimar Therapeutics profitable? | Yes, Larimar Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
